Summary of medicine characteristics - INFLUENZA VACCINE (SPLIT VIRION INACTIVATED), FLUARIX TETRA SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE
1 NAME OF THE MEDICINAL PRODUCT
Fluarix Tetra suspension for injection in pre-filled syringe Influenza vaccine (split virion, inactivated)
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
2 QUALITATIVE AND QUANTITATIVE COMPOSITIONInfluenza virus (inactivated, split) of the following strains*:
A/Victoria/2570/2019 (H1N1)pdm09 - like strain (A/Victoria/2570/2019, IVR-215)
A/Victoria/2570/2019 (H1N1)pdm09 – like strain (A/Victoria/2570/2019, IVR-215)15 micrograms HA
A/Cambodia/e0826360/2020 (H3N2) – like strain (A/Tasmania/503/2020, IVR-221)
15 micrograms HA
B/Washington/02/2019 – like strain (B/Washington/02/2019, wild type)
15 micrograms HA
B/Phuket/3073/2013 – like strain (B/Phuket/3073/2013, wild type) 15 micrograms HA
per 0.5 ml dose
* propagated in fertilized hens’ eggs from healthy chicken flocks
* * haemagglutinin
This vaccine complies with the World Health Organisation (WHO) recommendation (northern hemisphere) and EU recommendation for the 2021/2022 season.
Excipients with known effect
This product contains approximately 3.75 mg of sodium chloride and approximately 1.3 mg of disodium phosphate dodecahydrate per dose (see section 4.4).
This product contains approximately 0.2 mg of potassium dihydrogen phosphate and approximately 0.1 mg of potassium chloride per dose (see section 4.4).
Fluarix Tetra may contain traces of eggs (such as ovalbumin, chicken proteins), formaldehyde, gentamicin sulphate and sodium deoxycholate which are used during the manufacturing process (see section 4.3).
For the full list of excipients see section 6.1.
3 PHARMACEUTICAL FORM
Suspension for injection in pre-filled syringe.
The suspension is colourless and slightly opalescent.
4.1 Therapeutic indications
Fluarix Tetra is indicated for active immunisation of adults and children from 6 months of age for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus lineages contained in the vaccine (see section 5.1).
The use of Fluarix Tetra should be based on official recommendations.
Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus might change from year to year.
4.2 Posology and method of administration
Posology
Adults: 0.5 ml
Paediatric population
Children from 6 months onwards: 0.5 ml.
For children aged < 9 years, who have not previously been vaccinated against influenza, a
second dose should be given after an interval of at least 4 weeks.
Children less than 6 months: the safety and efficacy of Fluarix Tetra in children less than 6
months have not been established.
Method of administration
Immunisation should be carried out by intramuscular injection.
Precautions to be taken before handling or administering the medicinal product
For instructions for preparation of the medicinal product before administration, see section 6.6.
4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or to any component that may be present as traces such as eggs (ovalbumin, chicken proteins), formaldehyde, gentamicin sulphate and sodium deoxycholate.
Immunisation shall be postponed in patients with febrile illness or acute infection.
4.4 Special warnings and precautions for use
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable events) and a clinical examination.
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.
Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient.
Fluarix Tetra is not effective against all possible strains of influenza virus. Fluarix Tetra is intended to provide protection against those strains of virus from which the vaccine is prepared and to closely related strains.
As with any vaccine, a protective immune response may not be elicited in all vaccinees.
Fluarix Tetra should under no circumstances be administered intravascularly.
As with other vaccines administered intramuscularly, Fluarix Tetra should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.
Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.
Interference with serological testing.
See section 4.5.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium free”.
This medicine contains potassium, less than 1 mmol (39 mg) per dose, i.e. essentially “potassium free”.
4.5 Interaction with other medicinal products and other forms of interaction Fluarix Tetra can be concomitantly administered with pneumococcal polysaccharide vaccines in subjects aged 50 years and above (see section 5.1).
Fluarix Tetra can be concomitantly administered with adjuvanted herpes zoster vaccine (Shingrix) (see section 5.1).
If Fluarix Tetra is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.
The frequency of injection site pain reported in subjects vaccinated concomitantly with inactivated quadrivalent influenza vaccine (Fluarix Tetra) and 23-valent pneumococcal polysaccharide vaccine (PPV23) is similar to that observed with PPV23 alone, and higher compared to Fluarix Tetra alone.
Incidence of fatigue, headache, myalgia and shivering reported in subjects vaccinated concomitantly with Fluarix Tetra and Shingrix is similar to that observed with Shingrix alone, and higher compared to Fluarix Tetra alone.
Following influenza vaccination, false positive results in serology tests using the ELISA method to detect antibodies against HIV1, Hepatitis C and especially HTLV1 have been observed. The Western Blot technique disproves the false-positive ELISA test results. The transient false positive reactions could be due to the IgM response by the vaccine.
4.6 Fertility, pregnancy and lactation
Pregnancy
Inactivated influenza vaccines can be used in all stages of pregnancy. Larger datasets on safety are available for the second and third trimester, compared with the first trimester; however, data from worldwide use of inactivated influenza vaccines do not indicate any adverse foetal and maternal outcomes attributable to the vaccine.
Breast-feeding
Fluarix Tetra may be used during breast-feeding.
Fertility
No fertility data are available.
4.7 Effects on ability to drive and use machines
Fluarix Tetra has no or negligible influence on the ability to drive and use machines.
4.8 Undesirable effects
In all age groups the most frequently reported local adverse reaction after vaccination was injection site pain (15.6% to 40.9%).
In adults 18 years of age and above, the most frequently reported general adverse reactions after vaccination were fatigue (11.1%), headache (9.2%) and myalgia (11.8%).
In subjects aged 6 to 17 years, the most frequently reported general adverse reactions after vaccination were fatigue (12.6%), myalgia (10.9%) and headache (8.0%).
In subjects aged 3 to 5 years, the most frequently reported general adverse reactions after vaccination were drowsiness (9.8%) and irritability (11.3%).
In subjects aged 6 months to 3 years, the most frequently reported general adverse reactions after vaccination were irritability/fussiness (14.9%) and loss of appetite (12.9%).
Adverse reactions reported for Fluarix Tetra in the different age groups are listed per dose according to the following frequency categories:
Very common Common Uncommon Rare
Very rare
(>1/10)
(>1/100 to <1/10)
(>1/1,000 to <1/100)
(>1/10,000 to <1/1,000)
(<1/10,000)
Adults
A clinical study with Fluarix Tetra in adults has evaluated the incidence of adverse reactions in subjects >18 years who received one dose of Fluarix Tetra (N = 3,036) or Fluarix (trivalent influenza vaccine) (N = 1,010).
The following adverse reactions per dose have been reported:
| System Organ Class | Frequency | Adverse Reactions |
| Nervous system disorders | Common | Headache |
| Uncommon | Dizziness1 | |
| Gastrointestinal disorders | Common | Gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain) |
| Skin and subcutaneous tissue disorders | Common | Sweating2 |
| Musculoskeletal and connective tissue disorders | Very common | Myalgia |
| Common | Arthralgia | |
| General disorders and administration site conditions | Very common | Injection site pain, fatigue |
| Common | Injection site redness, injection site swelling, shivering, fever, injection site 2 induration | |
| Uncommon | Injection site hematoma1, injection site . i pruritus |
'‘Reported as unsolicited adverse reaction
2Reported in previous Fluarix trials
Children aged 6 months to <18 years
Two clinical studies evaluated the reactogenicity and safety of Fluarix Tetra in children who received at least one dose of Fluarix Tetra or a control vaccine.
One study enrolled children 3 to <18 years of age who received Fluarix Tetra (N = 915) or Fluarix (N = 912). The second study enrolled children 6 to <36 months of age who received Fluarix Tetra (N = 6,006) or a non-influenza vaccine control (N = 6,012) (see section 5.1).
The following adverse reactions per dose have been reported:
| System Organ Class | Adverse reactions | Frequency | ||
| 6 to <36 (months) | 3 to <6 (years) | 6 to <18 (years) | ||
| Metabolism and nutrition disorders | Loss of appetite | Very common | Common | N/A |
| Psychiatric disorders | Irritability/Fussiness | Very common | Very common | N/A |
| Nervous system disorders | Drowsiness | Very common | Common | N/A |
| Headache | N/A | N/A | Common | |
| Gastrointestinal disorders | Gastrointestinal symptoms (including nausea, diarrhoea, vomiting and/or abdominal pain) | N/A | N/A | Common |
| Skin and subcutaneous tissue disorders | Rash1 | N/R | Uncommon | Uncommon |
| Musculoskeletal and connective tissue disorders | Myalgia | N/A | N/A | Very common |
| Arthralgia | N/A | N/A | Common | |
| General disorders and administration site conditions | Fever (>38.0°C) | Common | Common | Common |
| Fatigue | N/A | N/A | Very common | |
| Injection site pain | Very | Very common | Very | |
| common | common | |||
| Injection site redness | Very common | Very common | Very common | |
| Injection site swelling | Common | Very common | Very common | |
| Shivering | N/A | N/A | Common | |
| Injection site pruritus1 | N/R | Uncommon | Uncommon | |
| Injection site 2 induration | N/A | Common | Common |
N/A=Not solicited in this age group
N/R=Not reported
1Reported as unsolicited adverse reaction
2Reported in previous Fluarix trials
The following adverse reactions have been observed for Fluarix and/or Fluarix Tetra during post-marketing surveillance1.
| System Organ Class | Frequency | Adverse events |
| Blood and lymphatic system disorders | Rare | Transient lymphadenopathy |
| Immune system disorders | Rare | Allergic reactions (including anaphylactic reactions) |
| Nervous system disorders | Rare | Neuritis, acute disseminated encephalomyelitis, Guillain-Barre syndrome2* |
| Skin and subcutaneous tissue disorders | Rare | Urticaria, pruritus, erythema, angioedema |
| General disorders and administration site conditions | Rare | Influenza-like illness, malaise |
1Three of the influenza strains contained in Fluarix are included in Fluarix Tetra.
2Spontaneous reports of Guillain-Barré syndrome have been received following vaccination with Fluarix and Fluarix Tetra; however, a causal association between vaccination and Guillain-Barré syndrome has not been established.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
4.9 Overdose
Overdosage is unlikely to have any untoward effect.
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Influenza vaccine, ATC Code: J07BB02
Mechanism of action
Fluarix Tetra provides active immunisation against four influenza virus strains (two A subtypes and two B lineages) contained in the vaccine.
Fluarix Tetra induces humoral antibodies against the haemagglutinins. These antibodies neutralise influenza viruses.
Specific levels of haemagglutination-inhibition (HI) antibody titre post-vaccination with inactivated influenza virus vaccines have not been correlated with protection from influenza illness but the HI antibody titres have been used as a measure of vaccine activity. In some human challenge studies, HI antibody titres of >1:40 have been associated with protection from influenza illness in up to 50% of subjects.
Pharmacodynamic effects
The efficacy of Fluarix Tetra was evaluated in clinical study D-QIV-004, a randomised, observer-blind, non-influenza vaccine-controlled trial conducted during influenza seasons 2011 to 2014. Healthy subjects aged 6 through 35 months were randomized (1:1) to receive Fluarix Tetra (N = 6,006) or a non-influenza control vaccine (N = 6,012). They were administered 1 dose (in case of history of influenza vaccination) or 2 doses, approximately 28 days apart.
Efficacy of Fluarix Tetra was assessed for the prevention of reverse transcription polymerase chain reaction (RT-PCR)-confirmed influenza A and/or B disease (moderate to severe and of any severity) due to any seasonal influenza strain. Starting 2 weeks post-vaccination until the end of the influenza season (approximately 6 months later), nasal swabs were collected following an influenza like event, and tested for influenza A and/or B by RT-PCR. All RT-PCR-positive specimens were further tested for viability in cell culture and to determine whether the viral strains matched those in the vaccine.
Fluarix Tetra met the predefined criteria for primary and secondary vaccine efficacy objectives presented in Table 1.
Table 1: Fluarix Tetra: Attack rates and vaccine efficacy in children 6–35 months of age (ATP (according to protocol) cohort for efficacy – time to event)
| Fluarix Tetra | Active comparator1 | Vaccine efficacy | ||||||
| N2 | n3 | Attack rate (n/N) (%) | N2 | n3 | Attack rate (n/N) (%) | % | CI | |
| Any severity Influenza6 | ||||||||
| RT-PCR confirmed | 5,707 | 344 | 6.03 | 5,697 | 662 | 11.62 | 49.8 | 41.8; 56.84 |
| Culture confirmed | 5,707 | 303 | 5.31 | 5,697 | 602 | 10.57 | 51.2 | 44.1; 57.65 |
| Culture confirmed vaccine matching strains | 5,707 | 88 | 1.54 | 5,697 | 216 | 3.79 | 60.1 | 49.1; 69.05 |
| Moderate to Severe Influenza7 | ||||||||
| RT-PCR confirmed | 5,707 | 90 | 1.58 | 5,697 | 242 | 4.25 | 63.2 | 51.8; 72.34 |
| Culture confirmed | 5,707 | 79 | 1.38 | 5,697 | 216 | 3.79 | 63.8 | 53.4; 72.25 |
| Culture confirmed vaccine matching strains | 5,707 | 20 | 0.35 | 5,697 | 88 | 1.54 | 77.6 | 64.3; 86.65 |
| Lower respiratory Illness RT-PCR Confirmed | 5,707 | 28 | 0.49 | 5,697 | 61 | 1.07 | 54.0 | 28.9; 71.05 |
| Acute Otitis media RT PCR-confirmed | 5,707 | 12 | 0.21 | 5,697 | 28 | 0.49 | 56.6 | 16.7; 78.85 |
CI: Confidence Interval
1Children received age appropriate non-influenza vaccine control
2Number of subjects included in the ATP cohort for efficacy – time to event. This cohort included subjects who met all eligibility criteria, who were followed for efficacy and complied with the study protocol until the episode.
3Number of subjects who reported at least one case in the reporting period
42-sided 97.5% confidence interval
52-sided 95% confidence interval
6 Influenza disease of any severity was defined as an episode of influenza-like illness (ILI, i.e. fever >38°C with any of the following: cough, runny nose, nasal congestion, or breathing difficulty) or a consequence of influenza virus infection [acute otitis media (AOM) or lower respiratory illness (LRI)].
7 Moderate to severe influenza was a subset of any influenza disease, with any of the following: fever >39°C, physician-diagnosed AOM, physician-diagnosed lower respiratory tract infection, physician-diagnosed serious extra-pulmonary complications, hospitalisation in the intensive care unit, or supplemental oxygen required for more than 8 hours.
Exploratory analyses were conducted on the Total Vaccinated Cohort including 12,018 subjects (N = 6,006 for Fluarix Tetra, N = 6,012 for control). Fluarix Tetra was efficacious in the prevention of moderate to severe influenza caused by each of the 4 strains (Table 2), even when there was significant antigenic mismatch with 2 of the vaccine strains (A/H3N2 and B/Victoria).
Table 2: Fluarix Tetra: Attack rates and vaccine efficacy for RT-PCR confirmed moderate to severe disease by Influenza A subtypes and Influenza B lineages in children 6–35 months of age (Total Vaccinated Cohort)
| Fluarix Tetra | Active comparator1 | Vaccine Efficacy | ||||||
| Strain | N2 | n3 | Attack rate (n/N) (%) | N2 | n3 | Attack rate (n/N) (%) | % | 95% CI |
| A | ||||||||
| H1N14 | 6,006 | 13 | 0.22 | 6,012 | 46 | 0.77 | 72.1 | 49.9; 85.5 |
| H3N25 | 6,006 | 53 | 0.88 | 6,012 | 112 | 1.86 | 52.7 | 34.8; 66.1 |
| B | ||||||||
| Victoria6 | 6,006 | 3 | 0.05 | 6,012 | 15 | 0.25 | 80.1 | 39.7; 95.4 |
| Yamagata7 | 6,006 | 22 | 0.37 | 6,012 | 73 | 1.21 | 70.1 | 52.7; 81.9 |
1Infants received age appropriate non-influenza vaccine control
2Number of subjects included in the Total Vaccinated cohort
3Number of subjects who reported at least one case in the reporting period
4 to 7Proportion of antigenic matching strains was 84.8%, 2.6%, 14.3% and 66.6%, for A/H1N1, A/H3N2, B/Victoria, and B/Yamagata, respectively.
Additionally, for RT-PCR confirmed cases of any severity, Fluarix Tetra reduced the risk of visits to the general practitioner by 47% (Relative Risk (RR): 0.53 [95% CI: 0.46; 0.61], i.e., 310 versus 583 visits) and to the emergency room by 79% (RR: 0.21 [95% CI: 0.09; 0.47], i.e., 7 versus 33 visits). The use of antibiotics was reduced by 50% (RR: 0.50 [95% CI: 0.42; 0.60], i.e., 172 versus 341 subjects).
A clinical study performed in more than 7,600 subjects in the Czech Republic and Finland evaluated the efficacy of Fluarix to prevent culture-confirmed influenza A and/or B cases for vaccine antigenically matched strains.
Subjects were monitored for influenza-like illness to be confirmed by culture (see table 3for results). Influenza-like illness was defined as at least one general symptom (fever >37.8°C and/or myalgia) and at least one respiratory symptom (cough and/or sore throat).
Table 3: Attack rates and Vaccine Efficacy against Illness associated with evidence of influenza A or B Infection in adults 18 to 64 years of age (Total Vaccinated Cohort)
| Attack Rates (n/N)1 | Vaccine Efficacy (95% CI2) | |||||
| N | n | % | % | LL3 | UL | |
| Antigenically matched, culture-confirmed Influenza4 | ||||||
| Fluarix | 5,103 | 49 | 1.0 | 66.9 | 51.9 | 77.4 |
| Placebo | 2,549 | 74 | 2.9 | – | – | – |
| All culture-confirmed Influenza (Matched, Unmatched and Untyped)5 | ||||||
| Fluarix | 5,103 | 63 | 1.2 | 61.6 | 46.0 | 72.8 |
| Placebo | 2,549 | 82 | 3.2 | – | – | – |
1n/N: number of case/total number of subjects
2CI: Confidence Interval
3LL: Lower Limit
4There were no vaccine matched culture-confirmed cases of A/New
Caledonia/20/1999 (H1N1) or B/Malaysia/2506/2004 influenza strains with Fluarix or placebo
5Of the 22 additional cases, 18 were unmatched and 4 were untyped; 15 of the 22 cases were A (H3N2) (11 cases with Fluarix and 4 cases with placebo).
In this study, immunogenicity was also evaluated.
Table 4: Post-vaccination GMT and seroconversion rates
| Adults 18 years to 64 years | Fluarix1 N=291 |
| GMT (95% CI) | |
| A/H1N1 | 541.0 (451.0;649.0) |
| A/H3N2 | 133.2 (114.6;154.7) |
| B (Victoria) | 242.8 (210.7;279.7) |
| Seroconversion rate (95% CI) | |
| A/H1N1 | 76.3% (71.0;81.1) |
| A/H3N2 | 73.9% (68.4;78.8) |
| B (Victoria) | 85.2% (80.6;89.1) |
1containing A/H1N1, A/H3N2 and B (Victoria lineage)
Post-vaccination seroprotection rates were 97.6% against A/H1N1, 86.9% against A/H3N2 and 96.2% against B (Victoria).
Immunogenicity of Fluarix Tetra was evaluated in terms of HI Geometric mean antibody titre (GMT) at 28 days after the last dose (children) or Day 21 (adults) and HI seroconversion rate (4-fold rise in reciprocal titre or change from undetectable [< 10] to a reciprocal titre of > 40).
In study D-QIV-004 (children 6–35 months), the evaluation was performed in a subcohort of 1,332 children (753 in the Fluarix Tetra group and 579 in the control group). The results are presented in Table 5.
The effect of a 2-dose priming schedule in D-QIV-004 was evaluated by assessing the immune response after revaccination one year later with 1 dose of Fluarix Tetra in study D-QIV-009. This study demonstrated that 7 days post-vaccination, immune memory in children 6 to 35 months of age had been elicited for all four vaccine strains.
Immunogenic non-inferiority of Fluarix Tetra was assessed versus Fluarix in children in study D-QIV-003 (approximately 900 children 3 to < 18 years of age in each treatment group who received one or two doses of either vaccine) and adults in study D-QIV-008 (approximately 1,800 subjects 18 years of age and older received 1 dose of Fluarix Tetra and approximately 600 subjects received 1 dose of Fluarix). In both studies, Fluarix Tetra elicited an immune response against the three strains in common that was non-inferior to Fluarix and a superior immune response against the additional B strain included in Fluarix Tetra. The results are presented in Table 5.
Table 5: Fluarix Tetra: Post-vaccination GMT and seroconversion rates (SCR) in children (6–35 months; 3 to < 18 years) and adults 18 years or older (According to Protocol Cohort)
| Children 6 to 35 months of age (D-QIV-004) | ||||
| Fluarix Tetra | Control1 | |||
| N=750–753 | N’=742–746 | N=578–579 | N’=566–568 | |
| GMT2 (95% CI) | Seroconversion rate2 (95% CI) | GMT2 (95% CI) | Seroconversion rate2 (95% CI) | |
| A/H1N1 | 165.3 (148.6;183.8) | 80.2% (77.2;83.0) | 12.6 (11.1;14.3) | 3.5% (2.2;5.4) |
| A/H3N2 | 132.1 (119.1;146.5) | 68.8% (65.3;72.1) | 14.7 (12.9;16.7) | 4.2% (2.7;6.2) |
| B (Victoria) | 92.6 (82.3;104.1) | 69.3% (65.8;72.6) | 9.2 (8.4;10.1) | 0.9% (0.3;2.0) |
| B (Yamagata) | 121.4 (110.1;133.8) | 81.2% (78.2;84.0) | 7.6 (7.0;8.3) | 2.3% (1.2;3.9) |
| Children 3 to < 18years (D-QIV-003) | ||||
| Fluarix Tetra | Fluarix3 | |||
| N=791 | N’=790 | N=818 | N’=818 | |
| GMT (95% CI) | Seroconversion rate (95% CI) | GMT (95% CI) | Seroconversion rate (95% CI) | |
| A/H1N1 | 386.2 (357.3;417.4) | 91.4% (89.2;93.3) | 433.2 (401.0;468.0) | 89.9% (87.6;91.8) |
| A/H3N2 | 228.8 (215.0;243.4) | 72.3% (69.0;75.4) | 227.3 (213.3;242.3) | 70.7% (67.4;73.8) |
| B (Victoria) | 244.2 (227.5;262.1) | 70.0% (66.7;73.2) | 245.6 (229.2;263.2) | 68.5% (65.2;71.6) |
| B (Yamagata) | 569.6 (533.6;608.1) | 72.5% (69.3;75.6) | 224.7 (207.9;242.9) | 37.0% (33.7;40.5) |
| Adults 18 years or older (D-QIV-008) | ||||
| Fluarix Tetra | Fluarix3 | |||
| N=1,809 | N’=1,801 | N=608 | N’=605 | |
| GMT (95% CI) | Seroconversion rate (95% CI) | GMT (95% CI) | Seroconversion rate (95% CI) | |
| A/H1N1 | 201.1 (188.1;215.1) | 77.5% (75.5;79.4) | 218.4 (194.2;245.6) | 77.2% (73.6;80.5) |
| A/H3N2 | 314.7 (296.8;333.6) | 71.5% (69.3;73.5) | 298.2 (268.4;331.3) | 65.8% (61.9;69.6) |
| B (Victoria) | 404.6 (386.6;423.4) | 58.1% (55.8;60.4) | 393.8 (362.7;427.6) | 55.4% (51.3;59.4) |
| B | 601.8 | 61.7% (59.5;64.0) | 386.6 | 45.6% |
| (Yamagata) | (573.3;631.6) | (351.5;425.3) | (41.6;49.7) | |
N = Number of subjects with post-vaccination results available (for GMT)
N’ = Number of subjects with both pre- and post-vaccination results available (for SCR)
1non-influenza vaccine control
2results from the immunogenicity subcohort
3 B (Yamagata) strain was not included in Fluarix
In clinical study D-QIV-010 involving 356 adults >50 years of age at risk for complications of influenza and pneumococcal diseases, subjects received Fluarix Tetra and 23-valent pneumococcal polysaccharide vaccine (PPV23) either concomitantly or separately. For all four Fluarix Tetra vaccine strains and the six pneumococcal serotypes (1, 3, 4, 7F, 14, and 19A) in PPV23 evaluated in the prespecified primary analysis, the immune response was non-inferior between the two treatment groups. Based on a descriptive analysis for six additional pneumococcal vaccine serotypes (5, 6B, 9V, 18C, 19F, and 23F), the immune response was comparable between groups, with 91.7% to 100% and 90.7% to 100% of subjects attaining seroprotective antibody levels against these serotypes in the separate and concomitant administration group respectively.
In clinical study Zoster-004, 828 adults > 50 years of age were randomised to receive 2 doses of Shingrix 2 months apart, administered either concomitantly at the first dose (N=413) or non-concomitantly (N=415) with one dose of Fluarix Tetra. The antibody responses to each vaccine were similar, whether administered concomitantly or non-concomitantly. Furthermore, immunological non-inferiority between concomitant and non-concomitant administration was demonstrated for all four strains included in Fluarix Tetra in terms of HI antibody GMTs.
5.2 Pharmacokinetic properties
Not applicable.
5.3 Preclinical safety data
Non-clinical data reveal no special hazards for humans based on conventional studies of acute toxicity, local tolerance, repeated dose toxicity and reproductive/developmental toxicity.
6 PHARMACEUTICAL PARTICULARS
6 PHARMACEUTICAL PARTICULARS6.1 List of excipients
Sodium chloride,
Disodium phosphate dodecahydrate,
Potassium dihydrogen phosphate,
Potassium chloride,
Magnesium chloride hexahydrate,
a-tocopheryl hydrogen succinate,
Polysorbate 80,
Octoxinol 10
Water for injections.
6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
6.3 Shelf life
1 year
6.4 Special precautions for storage
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Store in the original package in order to protect from light.
6.5 Nature and contents of container
0.5 ml suspension in pre-filled syringe (type I glass) with a plunger stopper (grey butyl rubber) and a tip cap (bromobutyl and synthetic polyisoprene type I rubber with or without needles in the following pack sizes:
– with 1 needle: pack sizes of 1 or 10
– with 2 needles: pack size of 1
– without needle: pack sizes of 1 or 10
Not all pack sizes may be marketed.
6.6 Special precautions for disposal and other handling
The vaccine should be allowed to reach room temperature before use.
Shake before use. Inspect visually prior to administration.
Instructions for administration of the vaccine presented in pre-filled syringe
To attach the needle to the syringe, refer to the below drawing.
Needle
Syringe plunger
Syringe barrel Syringe cap
1. Holding the syringe barrel in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.
2. To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock (see picture).
3. Remove the needle protector, which on occasion can be a little stiff.
4. Administer the vaccine.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
SmithKline Beecham Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS
Trading as:
GlaxoSmithKline UK
8 MARKETING AUTHORISATION NUMBER(S)
8 MARKETING AUTHORISATION NUMBER(S)PL 10592/0302
9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
9. DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATIONDate of first authorisation: 21 March 2013
Date of latest renewal: 06 June 2017